Enhancement of antibody response of turkeys to trivalent avian influenza vaccine by positively charged liposomal avridine adjuvant

Fatunmbi, Olufemi O.; Newman, John A.; Sivanandan, V.; Halvorson, David A.

doi:10.1016/0264-410x(92)90444-o

Cited by 16 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the oil phase, different adjuvants can be added to inactivated vaccine formulations to increase immunogenicity (62–65). Such adjuvants can include chemicals, microbial components, or proteins that increase the overall immune responses to vaccine antigens (66).…”

Section: Current Status Experimental and Commercial Ai Vaccines For Tmentioning

confidence: 99%

Strategies and challenges for eliciting immunity against avian influenza virus in birds

Swayne

Kapczynski

2008

Immunological Reviews

116

102

View full text Add to dashboard Cite

Vaccines and vaccination have emerged during the past two decades as essential tools in avian influenza (AI) control for poultry, because they increase resistance to infection, prevent illness and death, reduce virus replication and shed from respiratory and alimentary tracts, and reduce virus transmission to birds and mammals, including humans. Such protection in birds is primarily mediated by homosubtypic humoral immunity against the hemagglutinin protein, but cell-mediated and innate immunity contribute to protection in some bird species. The immune response to the neuraminidase protein can contribute to protection, but immunity to the viral internal proteins is generally not protective. Although, some preliminary studies with M2e protein in chickens suggest partial protection may be achievable. Historically, the H5 subtype AI vaccines have demonstrated broad homosubtypic protection, primarily against H5 high-pathogenicity (HP) AI viruses isolated in the early stages of outbreaks. However, as H5 viruses have become endemic and outbreaks prolonged, some drift variants with resistance to earlier H5 AI vaccines have emerged in Central America, China, Egypt, and Indonesia. How widespread such drift variants are will remain unknown until more detailed genetic and antigenic analyses are conducted on field isolates. Future vaccines will utilize biotechnology to produce new AI vaccine seed strains using HA genes more closely matching circulating field viruses. In addition, newer technologies for AI vaccines will improve vaccine coverage by using mass application technologies for example by drinking water, by spray, or via injection in ovo or at the hatchery.

show abstract

Section: Current Status Experimental and Commercial Ai Vaccines For Tmentioning

confidence: 99%

Strategies and challenges for eliciting immunity against avian influenza virus in birds

Swayne

Kapczynski

2008

Immunological Reviews

116

102

View full text Add to dashboard Cite

show abstract

“…In fact, from a preliminary study, this positively charged liposomal avridine vaccine was superior to the negatively charged or neutral liposomal avridine vaccine (Fatunmbi et al, 1992b). The vaccine with antigens covalently linked to avridine containing liposomes was less efficacious than the positively charged liposomal avridine vaccine.…”

Section: Discussionmentioning

confidence: 98%

Efficacy of avridine and liposomes as adjuvants for avian influenza virus antigens in Turkeys

et al. 1992

View full text Add to dashboard Cite

SUMMARYFour-week-old turkeys were vaccinated with H4N8, H5N2 and H7N3 inactivated avian influenza viruses (AIV) in one of the following adjuvants: avridine, positively charged liposomal avridine, liposomal avridine with covalent attachment to the AIV antigens and oil-emulsion; and without any adjuvant. Two vaccinations were given at a 4-week interval. Antibody concentrations in sera and in respiratory lavages were measured over a period of 8 weeks. The turkeys responded with high cumulative geometric mean HI titres to the H4N8, H5N2 and H7N3 components of the vaccines, while the cumulative geometric mean HI titres for the antigens without adjuvant were significantly (P < 0.05) lower.The most efficacious adjuvant, positively charged liposomal avridine, gave the highest local immune response as measured by total antibody specific to AIV in respiratory lavages. The difference in weight gains between vaccinated and non-vaccinated turkeys was significant (P<0.05). Virus isolations 2 weeks post-challenge decreased in vaccinated turkeys.

show abstract

“…Because PEG has been shown to improve the stability, pharmacokinetic and biodistribution profiles of gene-/oligo-delivery systems in vivo [25,26], the optimal LANC formulation is likely to have high siRNA transfection efficiency in vivo . Furthermore, Avridine, as a pharmacological active compound, has been reported to have immunoadjuvanticity [8,27,28] and interferon-stimulating activity [29]. Thus, coformulating Avridine and antiviral siRNA [2,30] in the LANCs will significantly alter the pharmacokinetic and biodistribution profiles of both molecules, which may be a potential strategy for combination therapy against viral infection.…”

Section: Future Perspectivementioning

confidence: 99%

“…For example, novel lipid-like materials synthesized using combinatorial chemistry, called lipidoids, were shown to have remarkable siRNA delivery activity in vitro and in vivo [6,7]. The key structural elements for the lipidoids were the amino alcohols containing polar secondary/tertiary amino head groups and hydrophobic hydrocarbon tails [8,9]. Avridine, a lipoidal amine composed of two tertiary amino groups and two nonpolar hydrocarbon chains (Figure 1A), had been used in the preparation of liposomes to enhance the efficacy of immunizing agents [8].…”

mentioning

confidence: 99%

“…The key structural elements for the lipidoids were the amino alcohols containing polar secondary/tertiary amino head groups and hydrophobic hydrocarbon tails [8,9]. Avridine, a lipoidal amine composed of two tertiary amino groups and two nonpolar hydrocarbon chains (Figure 1A), had been used in the preparation of liposomes to enhance the efficacy of immunizing agents [8]. Although Avridine ® shares structural similarity with the lipidoids, it has yet to be incorporated in a cationic NC formulation for siRNA delivery.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Novel Lipoidal amine-based Nanocarrier Formulations for siRNA Delivery

Zhou

Zhang

Lee

et al. 2012

Therapeutic Delivery

View full text Add to dashboard Cite

show abstract

Enhancement of antibody response of turkeys to trivalent avian influenza vaccine by positively charged liposomal avridine adjuvant

Cited by 16 publications

References 19 publications

Strategies and challenges for eliciting immunity against avian influenza virus in birds

Strategies and challenges for eliciting immunity against avian influenza virus in birds

Efficacy of avridine and liposomes as adjuvants for avian influenza virus antigens in Turkeys

Novel Lipoidal amine-based Nanocarrier Formulations for siRNA Delivery

Contact Info

Product

Resources

About